EmeritusDX, a rapidly growing cancer diagnostics and information company, today announced a definitive agreement to acquire Sprint Diagnostics (SprintDX), with the goal to expand its Pharma Services Division. This acquisition marks a significant milestone for EmeritusDX in its ongoing effort to enhance and diversify its service offerings within the pharmaceutical industry. Sprint Diagnostics brings a strong market presence and a reputation for innovative laboratory services that complement the existing capabilities of EmeritusDX.
Read the full article: EmeritusDX to Acquire Sprint Diagnostics to Expand Its Pharma Services Division //
Source: https://www.prweb.com/releases/emeritusdx-to-acquire-sprint-diagnostics-to-expand-its-pharma-services-division-302187601.html